Savara

SVRA

Market cap $1.22B

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to treat patients with autoimmune PAP. The FDA granted Priority Review with a PDUFA action date of August 22, 2026. “The FDA's filing of the BLA marks another significant milestone for Savara and the autoimmune PAP community and brings us one step closer to a potential.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 10, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 7,500 shares of the Company's common stock and restricted stock units (RSUs).

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will host one-on-one meetings and participate in fireside chats at two upcoming investor healthcare conferences. Fireside Chats: Guggenheim Emerging Outlook: Biotech Summit February 11th at 12:30pm ET Oppenheimer 36th Annual Healthcare Life Sciences Conference February 25th at 9:20am ET T.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity. Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA's approval of MOLBREEVI, the Company's investigational therapy in autoimmune pul.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 17,500 shares of the Company's common stock and restrict.

Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LANGHORNE, Pa.--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was req.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the drug substance manufacturer. The MOLBREEVI BLA submission is seeking approval for the treatment of autoimmune PAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. The Company has request.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: Wednesday, January 14, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan B.